Clinical Takeaway
Cannabis use for anxiety showed product-dependent effects, with CBD and combined THC+CBD products demonstrating more favorable daily anxiety reductions compared to THC alone. Both flower and edible delivery methods produced measurable but distinct longitudinal outcomes over 30 days. Patients and clinicians should consider cannabinoid composition and product form when evaluating cannabis as an anxiety management strategy.
#8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study provides empirical evidence for differential anxiolytic effects based on cannabis product formulation, which is critical for clinical counseling and treatment recommendations as patients increasingly seek cannabis as an anxiety intervention. The longitudinal daily assessment design reveals acute and sustained anxiety outcomes that challenge the assumption of uniform therapeutic benefit across product types, informing more precise dosing and product selection strategies. These findings establish a methodological foundation for identifying which patient populations and cannabis phenotypes produce clinically meaningful anxiety reduction, enabling evidence-based integration of cannabis into anxiety management protocols.
Quality Gate Alerts:
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
🧠 This study provides useful real-world data showing that cannabis flower and edibles may have differential effects on anxiety over time, with flower users reporting greater daily anxiety reductions in this self-selected cohort. However, several important caveats warrant caution in clinical interpretation: the study enrolled only participants motivated to use cannabis for anxiety, introducing significant selection bias that likely overestimates therapeutic benefit; there is no control group or placebo comparator, making it impossible to distinguish active drug effects from natural anxiety fluctuation or expectancy effects; and the study does not adequately control for baseline THC to CBD ratios between products, which substantially influence anxiolytic versus anxiogenic outcomes. The lack of validated anxiety measures and reliance on participant-reported daily assessments also limits confidence in the magnitude of reported effects. For practitioners, this work suggests that product formulation (flower versus edible) and cannabinoid profile may matter for individual anxiety management, but the evidence remains preliminary enough that patients should be counseled that cannabis for anxiety lacks robust clinical trial support
| |